Clinical complement inhibition by the anti-C5 antibody Eculizumab: Update on clinical trials

被引：0
|
作者：
Roeth, A. [1 ]
机构：
[1] Univ Klinikum Essen, Klin Hamatol, Essen, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：283 / 283
页数：1
相关论文
共 50 条
  • [1] Eculizumab - Humanized anti-C5 monoclonal antibody
    Harding, J
    DRUGS OF THE FUTURE, 2004, 29 (07) : 673 - 676
  • [2] DECADE Trial: Inhibition of theterminal complement system using the anti-C5 antibody eculizumab for the treatment of cold agglutinin disease (CAD)
    Roeth, A.
    Huettmann, A.
    Duehrsen, U.
    ONKOLOGIE, 2010, 33 : 112 - 112
  • [3] C3-glomerulopathy caused by a dysregulation of the alternative pathway of the complement system: improvement with the anti-C5 monoclonal antibody eculizumab
    Romano, F.
    Frassoni, E.
    Siegenthaler, G.
    Tschumi, S.
    Bucher, S. B.
    Simonetti, G. D.
    SWISS MEDICAL WEEKLY, 2015, 145 : 35 - 35
  • [4] Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.
    Thomas, TC
    Rollins, SA
    Rother, RP
    Giannoni, MA
    Hartman, SL
    Elliott, EA
    Nye, SH
    Matis, LA
    Squinto, SP
    Evans, MJ
    MOLECULAR IMMUNOLOGY, 1996, 33 (17-18) : 1389 - 1401
  • [5] RESPONSE OF A CHILD WITH FAMILIAL DYSREGULATION OF THE COMPLEMENT SYSTEM TO ANTI-C5 ANTIBODY
    Elnour, Ibtisam
    El-Naggari, Mohamed
    PEDIATRIC NEPHROLOGY, 2017, 32 (09) : 1748 - 1748
  • [6] Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model
    Wang, H
    Rollins, SA
    Gao, ZH
    Garcia, B
    Zhang, Z
    Xing, JJ
    Li, L
    Kellersmann, R
    Matis, LA
    Zhong, R
    TRANSPLANTATION, 1999, 68 (11) : 1643 - 1651
  • [7] Of Mice and Men: Terminal Complement Inhibition With Anti-C5 Monoclonal Antibodies
    Woodle, E. S.
    Baldwin, W. M., III
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (11) : 2277 - 2278
  • [8] Complement inhibition by anti-C5 antibodies - from bench to bedside and back again
    Trendelenburg, Marten
    SWISS MEDICAL WEEKLY, 2007, 137 (29-30) : 413 - 417
  • [9] Assessment of Eculizumab (Anti-C5) Therapy For Treatment of Severe Antibody-Mediated Rejection Episodes (ABMR)
    Jordan, S.
    Choi, J.
    Vo, A.
    Kahwaji, J.
    Peng, A.
    Villicana, R.
    Mark, H.
    TRANSPLANTATION, 2014, 98 : 437 - 437
  • [10] Assessment of Eculizumab (Anti-C5) Therapy For Treatment of Severe Antibody-Mediated Rejection Episodes (ABMR)
    Jordan, S.
    Choi, J.
    Vo, A.
    Kahwaji, J.
    Peng, A.
    Villicana, R.
    Mark, H.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 437 - 437
12345